-
Mashup Score: 0Transgender Patients With Breast Cancer Have Worse Outcomes Than Their Cisgender Peers - 2 day(s) ago
The worse overall survival seen in transgender and gender-diverse patients may be due to treatment differences or non-breast cancer causes, researchers say.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet
-
Mashup Score: 0The Grand Roundup - 3 day(s) ago
We are introducing a new way to deliver the most relevant information you need for your patients on the topics that matter most to your clinical practice.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Sign up today for our bi-weekly email covering emerging research, conference news, and guideline updates on general oncology, breast cancer and lung cancer: https://t.co/Yn7x746tB1 https://t.co/M8zAlDAuZQ
-
-
Mashup Score: 0
“The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Adding pembrolizumab to enzalutamide and ADT did not improve outcomes in patients with metastatic hormone-sensitive #prostatecancer who had not received prior treatment with next-generation hormonal agents. https://t.co/g5WCsQYbX5 #mHSPC #pcsm
-
-
Mashup Score: 2
Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
The costs of #adverseEvents from #cancerdrugs are consistently underestimated. Published in @JAMANetworkOpen. https://t.co/Tkk1npxqW0
-
-
Mashup Score: 0
Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer, according to data presented at #ASCO25. #bcsm https://t.co/WXwW8hcEP6 https://t.co/U2iixO4h7I
-
-
Mashup Score: 10
Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 IMforte trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 IMforte trial. Presented at #ASCO25 by @LuisPaz_Ares of @H12Octubre. #lcsm https://t.co/iX3gWReNqR https://t.co/PFin8Sp1fa
-
-
Mashup Score: 0
HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but a lack of OS benefit prompted the withdrawal of the BLA for HER3-DXd. Presented at #ASCO25 by @TonyMok9. #lcsm https://t.co/Y7pXas4omX https://t.co/1IGC5o18Ir
-
-
Mashup Score: 0TTFields Plus Chemo Deemed New Paradigm for Locally Advanced Pancreatic Adenocarcinoma - 5 day(s) ago
Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Combining TTFields with gemcitabine and nab-paclitaxel can improve OS when compared to chemotherapy alone in patients with locally advanced #pancreaticAdenocarcinoma. https://t.co/2Q3gBloVKe #pancsm #ASCO25
-
-
Mashup Score: 0TTFields Plus Chemo Deemed New Paradigm for Locally Advanced Pancreatic Adenocarcinoma - 5 day(s) ago
Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
Combining TTFields with gemcitabine and nab-paclitaxel can improve OS when compared to chemotherapy alone in patients with locally advanced #pancreaticAdenocarcinoma. https://t.co/2Q3gBloVKe #pancsm #ASCO25
-
-
Mashup Score: 2Pembrolizumab Doesn’t Improve Upon Enzalutamide for mCRPC - 6 day(s) ago
“As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor mutation burden-high prostate cancer,” the researchers concluded.
Source: www.cancertherapyadvisor.comCategories: General Medicine NewsTweet-
The combination of pembrolizumab and enzalutamide is no more effective than enzalutamide alone for patients with chemotherapy-naïve metastatic castration-resistant #prostateCancer according to research published in @myESMO Annals of Oncology. https://t.co/tATluhJtbq #mCRPC
-
Transgender and gender-diverse patients with #breastcancer are less likely to receive endocrine therapy for HR-positive disease and have worse survival outcomes than cisgender patients. Published in @JAMAOnc. https://t.co/Qx0EsEz3tP #bcsm